On Jan. 25, 2021, Nirmidas Biotech announced its second FDA Emergency Use Authorization (EUA) for their COVID-19 rapid antibody IgG/IgM test, now available for point-of-care (POC) settings. The MidaSpotﾙ COVID-19 Antibody Combo Detection Kit uses a fingerstick serology test for detecting antibodies against the RBD antigen on the surface of the SARS-CoV-2 virus.